Maximize Your Research Impact with Generativity’s Publication Services
In the competitive pharmaceutical landscape, effective communication of research findings is crucial for driving innovation, influencing clinical practice, and achieving commercial success. Generativity offers comprehensive publication services tailored to the unique needs of the pharmaceutical industry, ensuring your research reaches its full potential.
Our End-to-End Publication Support:
We provide expert assistance at every stage of the publication process, from conceptualization to submission:
Research Conceptualization: We help you define clear research questions, develop robust study designs, and identify appropriate target journals.
Manuscript Development: We transform your research data and insights into compelling manuscripts that meet the highest standards of scientific writing, ensuring clarity, accuracy, and adherence to journal guidelines.
Abstract and Poster Preparation: We create concise and impactful abstracts and visually engaging posters that effectively communicate your research findings at conferences and scientific meetings.
Journal Selection and Submission: We guide you through the journal selection process, ensuring your manuscript is submitted to the most appropriate journal for your target audience.
Peer Review and Revision: We assist with responding to reviewer comments, revising your manuscript, and navigating the peer review process to increase your chances of publication success.
Our Experience and Expertise:
Proven Track Record: We have a strong track record of publishing in top-tier medical journals.
Therapeutic Area Expertise: Our team possesses deep knowledge across a wide range of therapeutic areas, ensuring your publications are accurate, relevant, and impactful.
Publication Planning and Tracking: We have extensive experience with publication review platforms, such as a Datavision and PubStrat, to streamline the publication planning and tracking process.
Medical Writing and Editorial Assistance:
A selection of publications that we have developed.
This study aims to compare the adherence rates for patients new to CGM therapy and the costs of care for individuals who obtained CGM devices from a pharmacy versus acquisition through a durable medical equipment supplier using retrospective claims analysis.
Cladribine tablets and fingolimod have similar marketing authorisations in Europe for the treatment of patients with highly active relapsing multiple sclerosis (HA-RMS). In the absence of direct head-to-head studies, real-world data are important to assess the comparative effectiveness of these oral disease-modifying therapies (DMTs). The primary objective of the present study was to compare relapse rates between patients who received either cladribine tablets or fingolimod.
An innovative computational model was developed to address challenges regarding the evaluation of treatment sequences in patients with relapsing-remitting multiple sclerosis (RRMS) through the concept of a 'virtual' physician who observes and assesses patients over time. We describe the implementation and validation of the model, then apply this framework as a case study to determine the impact of different decision-making approaches on the optimal sequence of disease-modifying therapies (DMTs) and associated outcomes.
RATIONALE-301 (NCT03412773) was a global, phase 3 study comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in adult patients with unresectable hepatocellular carcinoma (HCC) that met its primary endpoint of noninferiority in overall survival (OS). This analysis compared health-related quality-of-life (HRQOL) outcomes between the arms.
This systematic literature review examines the current immune checkpoint inhibitors treatment paradigms, treatment gaps and unmet needs for treating SCLC with respect to efficacy, safety, health related quality of life (HRQoL) and cost-effectiveness.
Hereditary angioedema (HAE) is characterized by recurrent and unpredictable episodes of subcutaneous and/or submucosal swelling. To characterize the real-world treatment burden associated with existing on-demand therapies, we analyzed administration-site adverse drug reactions (ADR) associated with approved on-demand HAE therapies reported in the U.S. Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS).
Bendamustine hydrochloride (BND HCl) is indicated for first-line treatment of chronic lymphocytic leukemia (CLL) and rituximab-refractory indolent non-Hodgkin lymphoma (iNHL). There are two ready-to-dilute (RTD) formulations of BND HCl on the US market: a large-volume, long-duration infusion (BND-L) and a small-volume, short-duration infusion (BND-S). It is estimated that the shorter duration infusion could result in cost savings to infusion facilities.
Immune checkpoint inhibitors targeting the programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) axis (collectively referred to as PD[L]1i) have demonstrated clinical benefits in non-small cell lung cancer (NSCLC) patients. The purpose of this United States-based real-world study is to examine changes in the landscape of first-line therapies for NSCLC since the introduction of PD(L)1i.
This study estimated the cost-effectiveness of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) when used in first-line acute promyelocytic leukemia (APL) treatment.
